 OUTLINE: Patients undergo leukapheresis for the harvest of peripheral blood mononuclear cells PBMCs. PBMCs are stimulated with 2-methyl-3-butenyl-1-pyrophosphate and aldesleukin for 11 days. Patients then receive the expanded Gamma Delta T cells, aldesleukin, and zoledronic acid once a month for 6 months. 